Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
  • Patent number: 11497715
    Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 15, 2022
    Assignee: Cureport, Inc.
    Inventor: De-Min Zhu
  • Patent number: 11497692
    Abstract: Cosmetic blending devices for producing a cosmetic liquid from a solid-shell cosmetic ingredient capsule. The cosmetic blending devices include a lid, a base, a blending element configured to blend the capsule, and a drive mechanism configured to actuate the blending element. The cosmetic blending device may include a thermal element configured to change a temperature of the capsule. The thermal element may melt the capsule. The solid-shell cosmetic ingredient capsule comprises a shell defining an enclosed inner volume, and cosmetic material included in the enclosed inner volume. Methods of using the cosmetic blending devices comprise placing the solid-shell cosmetic ingredient capsule into the cosmetic blending device and blending the capsule to produce the cosmetic liquid. Methods of forming the solid-shell cosmetic ingredient capsule comprise forming a portion of the shell, adding the cosmetic material to the portion of the shell, and forming the remaining portion of the shell.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: November 15, 2022
    Assignee: REA Innovations, Inc.
    Inventors: Robb Akridge, Gregory Calvin Peterson
  • Patent number: 11466089
    Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: October 11, 2022
    Assignee: Ablynx N.V.
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Patent number: 11446336
    Abstract: The invention provides a composition comprising a bacterial strain of the genus Parabacteroides, for use in a method of treating or preventing cancer in a subject; wherein the cancer comprises oncogenic ERK signalling.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: September 20, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Anna Ettorre, Suaad Ahmed, Parthena Fotiadou
  • Patent number: 11439698
    Abstract: The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: September 13, 2022
    Assignee: Arytha Biosciences, LLC
    Inventor: Che-Ming Jack Hu
  • Patent number: 11439684
    Abstract: Provided herein are materials and methods for assessing ratios of lymphocyte to monocytes in cancer patients and, based on the ratios, treating the cancer patients with an immunotherapeutic.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 13, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Luis F. Porrata, Svetomir N. Markovic
  • Patent number: 11439579
    Abstract: The present invention concerns a sphere, characterized in that it comprises at least one polymer of hyaluronate and glucomannan. It also concerns a polymer of hyaluronate and glucomannan characterized in that each bond between a hyaluronate group and a glucomannan group is an ester bond. In addition, it concerns their production process and their use, in particular as a filling or hydration agent.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: September 13, 2022
    Assignee: BASF Beauty Care Solutions France SAS
    Inventors: Isabelle Bonnet, Florent Durieux, Eric Nappi
  • Patent number: 11433086
    Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: September 6, 2022
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, William E. Fogler
  • Patent number: 11419819
    Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: August 23, 2022
    Inventor: Oliver Denk
  • Patent number: 11413329
    Abstract: The present invention is directed to cancer cell traps and methods of using cancer cell traps to treat and detect metastatic cancer in subjects. The cancer cell traps are administered to subjects and induce the migration and accumulation of metastatic cancer cells in the cancer cell traps.
    Type: Grant
    Filed: October 19, 2013
    Date of Patent: August 16, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Liping Tang
  • Patent number: 11401312
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 2, 2022
    Assignees: Cytune Pharma, Institut Gustave Roussy (IGR)
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • Patent number: 11395802
    Abstract: Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 26, 2022
    Assignees: Auburn University, Altimmune, Inc.
    Inventors: Allan E. David, Henry J. Baker, Aime K. Johnson, M. Scot Roberts, Kent R. Van Kampen, Prachi Sangle
  • Patent number: 11388907
    Abstract: A method of preparing a lysolecithin composition. The method includes the steps of (a) providing a lecithin mixture including a lecithin, water, and ethanol, (b) adding phospholipase A1 or A2 to the lecithin mixture; and (c) allowing an enzymatic reaction to occur so that at least 70% of the phospholipids in the lecithin are converted to lysophospholipids to obtain the lysolecithin composition. Also disclosed are a lysolecithin composition thus prepared, a flavor emulsion prepared from the lysolecithin composition, and a liquid beverage or liquid beverage concentrate containing the lysolecithin composition.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: July 19, 2022
    Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Ying Yang, Daniel Kaiping Lee, Chii-Fen Wang
  • Patent number: 11382754
    Abstract: The present invention provides a technological platform for bone regeneration. More specifically, the invention provides an implant comprising a plurality of polymeric casings at least one of which encases a bone void filler and at least one reinforcement component. Also provided is a method of regenerating bone by implanting one or more implants according to the present invention to a bone repair site.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 12, 2022
    Assignee: TRACERAY OY
    Inventor: Yulia Kulkova
  • Patent number: 11384120
    Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 12, 2022
    Assignee: NIBEC CO., LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
  • Patent number: 11376218
    Abstract: The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 5, 2022
    Assignee: Versantis AG
    Inventors: Jean-Christophe Leroux, Vincent Forster, Valentina Agostoni
  • Patent number: 11357849
    Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 14, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Daniel Fernandes, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
  • Patent number: 11357728
    Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: June 14, 2022
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Chunlei Li, Lan Zhang, Caixia Wang, Li Zhang, Dongmin Shen, Yanhui Li, Xian Xiu, Min Liang, Yongfeng Li
  • Patent number: 11352398
    Abstract: Disclosed is a novel recombinant protein UK 114 in stable polymer form for use in the treatment, diagnosis and prevention of malignant solid and systemic tumours.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 7, 2022
    Inventor: Alberto Bartorelli Cusani
  • Patent number: 11352392
    Abstract: The invention discloses an artificially synthesized peptide H-473 and use thereof. The peptide H-473 has an amino acid sequence of RGLRGLR, a molecular weight of 827 Da and a PI of 12.30. The invention further discloses use of the peptide H-473 in anti-cancer, anti-senile dementia, analgesia and the like. The peptide H-473 provides scientific basis and direction for research and development of anti-cancer, anti-asthma, anti-senile dementia and analgesia, provides a valuable resource for studying mechanisms of anti-cancer, anti-asthma, anti-senile dementia, analgesia and anti-psoriasis, and provides a new direction for researching novel means for anti-cancer, anti-asthma, anti-senile dementia, analgesia, anti-psoriasis and anti-age-related macular degeneration (AMD).
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 7, 2022
    Inventors: Yiling Hou, Wanru Hou, Xiang Ding
  • Patent number: 11324770
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: May 10, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11318098
    Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: May 3, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
  • Patent number: 11304903
    Abstract: The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Oxford University Innovation Limited, Katholieke Universiteit Leuven
    Inventors: John Hagan Pryce Bayley, Kunwar Tanuj Sapra, Giovanni Maglia, Mariam Mohamed Abdelsattar Bayoumi
  • Patent number: 11298320
    Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: April 12, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
  • Patent number: 11291682
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: April 5, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
  • Patent number: 11278629
    Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 22, 2022
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Francesco Bertoni, Angela Romanelli, Callum Sloss
  • Patent number: 11260027
    Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 1, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Satish Nadig, Carl Atkinson, Ann-Marie Broome, Suraj K. Dixit
  • Patent number: 11248748
    Abstract: A drag reducing composition comprises a sealed temporary container; and a drag reducing agent and up to 20 weight percent of a dispersing fluid disposed in the sealed temporary container. The drag reducing agent comprises polyolefin particles having a particle size of about 10 to about 2,000 microns; and the dispersing fluid comprising water, an alcohol, a hydrocarbon, or a combination comprising at least one of the foregoing.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 15, 2022
    Assignee: BAKER HUGHES OILFIELD OPERATIONS LLC
    Inventors: Brandon M. Vittur, Jian Zou
  • Patent number: 11235070
    Abstract: This invention provides nanoparticles containing protein-polynucleotide complexes and methods of manufacture and methods of their use. These particles, when administered to a subject in need, are capable of delivering these complexes to target cells and target intracellular locations where they can perform a therapeutic function. In some embodiments, this therapeutic function includes gene editing, induction of gene skipping, and regulation of gene expression. The instant nanoparticles are generally formed by designing and synthesizing the polynucleotide to according to its intended function, combining it with a protein selected for its substrate specificity and enzymatic function in a manner to form a polynucleotide-protein complex, encapsulating the complexes by dispersion into a water-insoluble surfactant system, optionally adding a targeting ligand, and stabilizing the nanoparticles by crystallization of the ligand to the surface of the nanoparticles.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Asklepios Biopharmaceutical, Inc.
    Inventors: Gretchen M. Unger, Vicci Korman
  • Patent number: 11229616
    Abstract: Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: January 25, 2022
    Assignee: PHARMOSA BIOPHARM INC.
    Inventors: Pei Kan, Yi Fong Lin, Ko Chieh Chen
  • Patent number: 11229645
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 25, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11224614
    Abstract: Compositions containing iron and denatured protein have been prepared that are capable of increasing serum iron and other divalent metal cations in a subject. For example, edible microbeads have been prepared containing iron entrapped within a protein matrix that provides a gastroprotective effect and improves iron bioavailability relative to previously known vehicles for delivering iron to a subject.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: January 18, 2022
    Assignee: Solvotrin Therapeutics Limited
    Inventors: John Gilmer, Gabor Radics, Michael Whelehan, Jun Wang, Pat O'Flynn, Mark Ledwidge
  • Patent number: 11214805
    Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: January 4, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Ann-Marie Broome, Suraj Dixit, Satish Nadig, Carl Atkinson
  • Patent number: 11207269
    Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 28, 2021
    Assignee: BIO-BEDST APS
    Inventors: Morten Just Petersen, Fredrik Melander, Anders Falk Vikbjerg, Sune Allan Petersen, Mogens Winkel Madsen
  • Patent number: 11207379
    Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: December 28, 2021
    Assignee: IDP DISCOVERY PHARMA, S.L.
    Inventors: Santiago Esteban Martín, Laura Nevola
  • Patent number: 11197831
    Abstract: A composition is described that includes lipid microcapsules and at least one dispersed active principle. A method is also described for preparing the composition. Also described, is the use of the composition in the treatment of dermatological diseases.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 14, 2021
    Assignee: GALDERMA RESEARCH AND DEVELOPMENT
    Inventors: Carole Dubayle, Claire Mallard, Nicolas Atrux-Tallau
  • Patent number: 11191804
    Abstract: An object of the present invention is to provide a peptide drug that is able to selectively induce apoptosis in target cells. The present invention is a cytocidal agent containing a fusion peptide of an endosome escape peptide and an apoptosis-inducing peptide, which consists of an amino acid sequence represented by SEQ ID NO: 1, and the said cytocidal agent as a therapeutic agent for a disease caused by abnormal proliferation of cells.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 7, 2021
    Assignee: FUJITA ACADEMY
    Inventors: Kazuhiro Sugihara, Naohiro Kanayama, Toshiaki Shibata, Yuichiro Onodera
  • Patent number: 11185506
    Abstract: Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: November 30, 2021
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Paige N. Davis, Louie D. Garcia, Stephanie M. Kurz, Kathleen D. A. Los
  • Patent number: 11167009
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: November 9, 2021
    Assignees: INSTITUTO MASSONE S.A.
    Inventors: Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band, Elena M. V. de Cavanagh
  • Patent number: 11166913
    Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 9, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
  • Patent number: 11166914
    Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: November 9, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
  • Patent number: 11154638
    Abstract: A method of forming a scaffold is disclosed herein. In some embodiments, a method of forming a scaffold includes dissolving a polymer in a solvent to form a polymer solution; adding additive precipitating agent to the polymer solution; precipitating and expanding the polymer from the polymer solution to form a scaffold; and removing the solvent from the scaffold. In some embodiments, prior to adding the precipitating agent, the method further comprising adding at least one of calcium phosphate or a bioactive additive to the polymer solution to form a mixture including the polymer solution and the at least one of calcium phosphate or bioactive additive.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 26, 2021
    Assignee: Howmedica Osteonics Corp.
    Inventors: James Dominic San Antonio, Marc Gilles Long
  • Patent number: 11147881
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 19, 2021
    Assignees: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • Patent number: 11147811
    Abstract: The present invention relates to a comprising (A) an active ingredient which is hardly soluble in water, but soluble in a C1-4 lower alcohol that may contain 30 vol % or less water, (B) polyvinyl alcohol having a saponification rate of 55-99%, and (C) a non-ionic surfactant, wherein the (A) active ingredient has a mean particle size of 10-300 nm, and a process thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: October 19, 2021
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Shunsuke Saito
  • Patent number: 11130776
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: September 28, 2021
    Inventors: Anne Lespine, Roger Prichard, Cecile Menez
  • Patent number: 11110061
    Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: September 7, 2021
    Inventors: Byung Chul Shin, Sun Hang Cho, Tae Kyung Yang, Seok Hee Kang, Eun Hee Park
  • Patent number: 11111300
    Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: September 7, 2021
    Assignee: APOLLOMICS INC.
    Inventors: Jiping Zha, Ziyong Sun, Junzhuan Qiu
  • Patent number: 11103486
    Abstract: The present invention provides novel methods for treating Th2-mediated immune disorders and enhancing Th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (SGK1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught. The present invention also provides methods for augmenting the treatment of subjects having viral or parasitic infections, or which have cancerous tumors.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 31, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan David Powell, Emily Beth Heikamp
  • Patent number: 11103523
    Abstract: The invention provides amphiphilic liquid crystalline brush block copolymers that can readily self-assemble to nanoparticles in aqueous solutions and also allow for encapsulation of hydrophobic pharmaceutically active molecules.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 31, 2021
    Assignee: University of Connecticut
    Inventors: Xiuling Lu, Rajeswari Kasi, Thanh-Huyen Tran, Chi Thanh Nguyen, Prashant Deshmukh
  • Patent number: 11096898
    Abstract: A membrane including a barrier having layers of alginate with different material molar concentrations relative to another material. The layers have a uniform consistency across a thickness of the layers. The thickness is free of laminae and interfaces and forms a single layer morphology that provides permeability for selected molecules.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: August 24, 2021
    Assignee: GH CARE INC.
    Inventors: Giuseppe Pietro Pio Basta, Pia Montanucci, Riccardo Calafiore